Gail H Cassell

Gail H Cassell, Ph.D.

Bio
Research
Publications

Dr. Cassell is vice president for TB Drug Development at the Infectious Disease Research Institute in Seattle, Washington, professor emeritus and former chair, Department of Microbiology, University of Alabama at Birmingham, and former vice president for scientific affairs and distinguished Lilly research scholar for infectious diseases at Eli Lilly and Company in Indianapolis, Indiana. She founded the Forum on Drug Discovery, Development and Translation, which she continues to co-chair, at the Institute of Medicine. She has a distinguished record of national service with the National Academy of Sciences, National Institutes of Health, Centers for Disease Control, and several other national and international institutions.

Affiliations:

Division of Global Health Equity, Brigham and Women's Hospital

Dr. Cassell is a leader on efforts to address multidrug-resistant tuberculosis (MDRTB). She and Barry Bloom, former dean of Harvard School of Public Health, co-lead an Institute of Medicine project on drug supply chain issues related to MDRTB. She actively advises numerous government agencies, NGOs, and foundations on the scale-up of MDRTB diagnosis and treatment in endemic areas around the world, including in Russia. Dr. Cassell is advising the GHSM Sentinel Project on pediatric drug-resistant tuberculosis, a global partnership that aims to develop and deploy evidence-based strategies to prevent child deaths from drug-resistant tuberculosis.

Mycoplasma pulmonis possesses a novel chemoattractant for B lymphocytes.

Authors: Authors: Ross SE, Simecka JW, Gambill GP, Davis JK, Cassell GH.
Infect Immun 1992-02-01
View full abstract on Pubmed

Antibiotic susceptibilities and therapeutic options for Ureaplasma urealyticum infections in neonates.

Authors: Authors: Waites KB, Crouse DT, Cassell GH.
Pediatr Infect Dis J 1992-01-01
View full abstract on Pubmed

Infection and labor. VII. Microbial invasion of the amniotic cavity in spontaneous rupture of membranes at term.

Authors: Authors: Romero R, Mazor M, Morrotti R, Avila C, Oyarzun E, Insunza A, Parra M, Behnke E, Montiel F, Cassell GH.
Am J Obstet Gynecol 1992-01-01
View full abstract on Pubmed

Dendritic cells are present in the alveolar region of lungs from specific pathogen-free rats.

Authors: Authors: Simecka JW, Thorp RB, Cassell GH.
Reg Immunol 1992-01-01
View full abstract on Pubmed

Mycoplasmal infections of cerebrospinal fluid in children undergoing neurosurgery for hydrocephalus.

Authors: Authors: Waites KB, Duffy LB, Baldus K, Aronin PA, Cassell GH.
Pediatr Infect Dis J 1991-12-01
View full abstract on Pubmed

Cytopathic effects of Mycoplasma pulmonis in vivo and in vitro.

Authors: Authors: Stadtländer CT, Watson HL, Simecka JW, Cassell GH.
Infect Immun 1991-11-01
View full abstract on Pubmed

Specific and nonspecific antibody responses in different segments of the respiratory tract in rats infected with Mycoplasma pulmonis.

Authors: Authors: Simecka JW, Patel P, Davis JK, Ross SE, Otwell P, Cassell GH.
Infect Immun 1991-10-01
View full abstract on Pubmed

Protein and antigen heterogeneity among strains of Mycoplasma fermentans.

Authors: Authors: Städtlander CT, Zuhua C, Watson HL, Cassell GH.
Infect Immun 1991-09-01
View full abstract on Pubmed

Perinatal mycoplasmal infections.

Authors: Authors: Cassell GH, Waites KB, Crouse DT.
Clin Perinatol 1991-06-01
View full abstract on Pubmed

In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

Authors: Authors: Waites KB, Duffy LB, Schmid T, Crabb D, Pate MS, Cassell GH.
Antimicrob Agents Chemother 1991-06-01
View full abstract on Pubmed